Literature DB >> 7505975

Influence of patient age on the serum PSA concentration. An important clinical observation.

J E Oesterling1, W H Cooner, S J Jacobsen, H A Guess, M M Lieber.   

Abstract

Although PSA is a most valuable tool for the practicing physician, it lacks sufficient sensitivity and specificity for detecting early prostate cancer to be the perfect tumor marker. The parameters PSAD and PSA velocity are useful attempts to make PSA a better tumor marker, but they likewise are not always reliable on an individual basis. There is now evidence from several investigations that the serum PSA concentration in healthy men without clinical evidence of prostate cancer increases with advancing age. This is primarily attributable to the concomitant increase in prostate size over the same time period. As a result, age-specific reference ranges have been determined and have the potential to make PSA a more sensitive tumor marker for men less than 60 years of age and a more specific tumor marker for men beyond 60 years of age. If one utilizes the age-specific reference ranges for serum PSA, it appears that PSAD can be eliminated as a parameter in the diagnostic evaluation of patients suspected of having prostate cancer. Thus, a new algorithm utilizing age-specific reference ranges has been developed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505975

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  16 in total

1.  Screening for prostate cancer today.

Authors:  J N Kabalin
Journal:  West J Med       Date:  1995-03

2.  Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.

Authors:  Mohammed Nizar G Battikhi; Hussein Ismail; Qusey Battikhi
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

3.  Clinicopathological study of prostatic biopsies.

Authors:  A Josephine
Journal:  J Clin Diagn Res       Date:  2014-09-20

4.  Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.

Authors:  C Dinçel; T Caşkurlu; A I Taşçi; M Cek; G Sevin; A Fazlioğlu
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

5.  Image-based clinical decision support for transrectal ultrasound in the diagnosis of prostate cancer: comparison of multiple logistic regression, artificial neural network, and support vector machine.

Authors:  Hak Jong Lee; Sung Il Hwang; Seok-Min Han; Seong Ho Park; Seung Hyup Kim; Jeong Yeon Cho; Chang Gyu Seong; Gheeyoung Choe
Journal:  Eur Radiol       Date:  2009-12-17       Impact factor: 5.315

6.  Age-specific PSA reference ranges in Chinese men without prostate cancer.

Authors:  Zhi-Yong Liu; Ying-Hao Sun; Chuan-Liang Xu; Xu Gao; Luo-Man Zhang; Shan-Cheng Ren
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

7.  Safety and efficacy of combined transrectal ultrasound-guided prostate needle biopsy and transurethral resection of the prostate.

Authors:  Jeong Man Cho; Seung Wook Lee; Jung Yoon Kang; Tag Keun Yoo
Journal:  Korean J Urol       Date:  2010-02-18

Review 8.  Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.

Authors:  S Jain; A G Bhojwani; J K Mellon
Journal:  Postgrad Med J       Date:  2002-11       Impact factor: 2.401

9.  A study of PSA values in an unselected sample of Senegalese men.

Authors:  Mohamed Jalloh; Charnita Zeigler-Johnson; Marguette Sylla-Niang; Lamine Niang; Issa Labou; Karamo A Konte; Timothy R Rebbeck; Serigne Gueye
Journal:  Can J Urol       Date:  2008-02       Impact factor: 1.344

Review 10.  Screening for prostate cancer.

Authors:  M L Cher; P R Carroll
Journal:  West J Med       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.